Skip to main content

Published locations for BALL score predicts benefit from ibrutinib therapy in relapsed/refractory CLL patients

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. BALL score predicts benefit from ibrutinib therapy in relapsed/refractory CLL patients

User login

  • Reset your password
  • /content/ball-score-predicts-benefit-ibrutinib-therapy-relapsed/refractory-cll-patients
  • /hematologynews/article/226842/cll/ball-score-predicts-benefit-ibrutinib-therapy-relapsed/refractory
  • /internalmedicinenews/article/226842/cll/ball-score-predicts-benefit-ibrutinib-therapy-relapsed
  • /oncologypractice/article/226842/cll/ball-score-predicts-benefit-ibrutinib-therapy-relapsed
  • /hematology-oncology/article/226842/cll/ball-score-predicts-benefit-ibrutinib-therapy-relapsed
  • /internalmedicine/article/226842/cll/ball-score-predicts-benefit-ibrutinib-therapy-relapsed
  • /b-cell-lymphoma-icymi/article/226842/cll/ball-score-predicts-benefit-ibrutinib-therapy-relapsed